Published in Cancer Res on March 01, 1997
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
The normal structure and function of CD44 and its role in neoplasia. Mol Pathol (1998) 1.44
Pathobiology of brain metastases. J Clin Pathol (2005) 1.29
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
The role of metastasis suppressor genes in metastatic dormancy. APMIS (2008) 1.21
Metastasis suppressors and their roles in breast carcinoma. J Mammary Gland Biol Neoplasia (2007) 1.16
Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J (2012) 1.07
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys (2010) 1.04
Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep (2012) 1.03
Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol Cancer (2012) 1.02
Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis (1999) 1.00
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol (2009) 0.93
Cancer Stem Cells: A Moving Target. Curr Pathobiol Rep (2013) 0.92
Invasive behavior of ulcerative colitis-associated carcinoma is related to reduced expression of CD44 extracellular domain: comparison with sporadic colon carcinoma. Diagn Pathol (2011) 0.90
Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget (2015) 0.90
MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer (2011) 0.89
Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis (2000) 0.89
De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol (1998) 0.89
Heterogeneous Expression of Invasive and Metastatic Properties in a Prostate Tumor Model. Pathol Oncol Res (1997) 0.87
ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma. Virchows Arch (2007) 0.86
A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Res (2014) 0.85
CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer Progression. Genes Cancer (2011) 0.83
The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant. Oncol Lett (2012) 0.82
Down-regulation of Lsm1 is involved in human prostate cancer progression. Br J Cancer (2002) 0.81
Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice. PLoS One (2013) 0.77
Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology (2015) 0.77
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. BMC Cancer (2014) 0.75
Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis. Oncotarget (2016) 0.75
Akt signaling is sustained by a CD44 splice isoform-mediated positive feedback loop. Cancer Res (2017) 0.75
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
Prevalence of vitamin B12 deficiency among geriatric outpatients. J Fam Pract (1992) 3.52
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst (1998) 3.13
A DNA-activated protein kinase from HeLa cell nuclei. Mol Cell Biol (1990) 2.95
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J (2010) 1.84
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Physician-patient discussions of controversial cancer screening tests. Am J Prev Med (2001) 1.80
Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res (2000) 1.68
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst (1991) 1.57
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res (1994) 1.53
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ (2001) 1.43
Decline of serum cobalamin levels with increasing age among geriatric outpatients. Arch Fam Med (1994) 1.39
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
A novel membrane-bound glutathione S-transferase functions in the stationary phase of the yeast Saccharomyces cerevisiae. J Biol Chem (1998) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 1.22
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate (1990) 1.17
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 1.17
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis (1996) 1.16
KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am J Pathol (2001) 1.14
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res (1998) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res (1995) 1.11
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res (1999) 1.11
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer (1999) 1.10
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ (2002) 1.08
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate (2000) 1.07
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem (2001) 1.07
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate (1984) 1.06
Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer (2006) 1.05
Prostate tumor biology and cell kinetics--theory. Urology (1981) 1.05
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 1.04
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. Cell Calcium (1999) 1.03
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate (1999) 1.02
Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res (2000) 1.02
Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat. Cancer Res (1986) 1.02
Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res (1992) 1.01
Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology (1988) 0.99
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate (2000) 0.98
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer (1997) 0.98
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol (1981) 0.98
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate (1997) 0.98
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem (1999) 0.98
Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer (1992) 0.98
Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res (1998) 0.98
Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent. J Urol (1982) 0.97
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res (2001) 0.97
Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res (1993) 0.97
Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate (1988) 0.95
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate (1992) 0.95
Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology (1993) 0.94
Pathophysiology and significance of malabsorption after Roux-en-Y reconstruction. Surgery (1977) 0.94
Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate (1983) 0.94
The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res (1992) 0.94
"Thymineless" death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun (1989) 0.93
Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal. Jpn J Cancer Res (1995) 0.93
Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res (1994) 0.93
An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics (2001) 0.93
Prevalence and types of androgenetic alopecia in Shanghai, China: a community-based study. Br J Dermatol (2008) 0.92
The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res (1984) 0.92
Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate (1987) 0.91
The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU Int (2004) 0.91
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res (2001) 0.91
Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol (2000) 0.91